Among the notable releases from emerging-market companies, DRECOM revised its current fiscal year operating profit forecast upward from ¥1.0 billion to ¥1.3 billion, TMS announced the execution of a term sheet for a clinical trial of glioblastoma using NOX-A12 and the establishment of a subsidiary, and HOPE also revised its earnings forecast.
DRECOM revised its current fiscal year operating profit forecast upward from ¥1.00 billion to ¥1.30 billion.
TMS announced that it plans to enter into a term sheet for a clinical trial in patients with newly diagnosed glioblastoma and establish a related subsidiary.
HOPE revised its earnings forecast and presented new figures for its current fiscal year outlook.